Bank Of New York Mellon Corp Karuna Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$191.53 - $236.82 $41.4 Million - $51.2 Million	216,398 New	216,398 $42.5 Million
Q3 2022 Nov 14, 2022	SELL	$123.79 - $277.42 $5.64 Million - $12.6 Million	-45,537 Reduced 17.23%	218,802 $49.2 Million
Q2 2022 Aug 15, 2022	BUY	$93.97 - $143.33 $4.95 Million - $7.55 Million	52,661 Added 24.88%	264,339 $33.4 Million
Q1 2022 May 11, 2022	BUY	$98.9 - $132.37 $11.9 Million - $16 Million	120,709 Added 132.69%	211,678 $26.8 Million
Q4 2021 Feb 11, 2022	BUY	$110.64 - $159.4 $169,279 - $243,882	1,530 Added 1.71%	90,969 $11.9 Million
Q3 2021 Nov 12, 2021	BUY	$101.2 - $125.87 $821,946 - $1.02 Million	8,122 Added 9.99%	89,439 $10.9 Million
Q2 2021 Aug 11, 2021	BUY	$107.45 - $135.95 $2.17 Million - $2.75 Million	20,239 Added 33.14%	81,317 $9.27 Million
Q1 2021 May 13, 2021	SELL	$95.46 - $133.08 $361,888 - $504,506	-3,791 Reduced 5.84%	61,078 $7.34 Million
Q4 2020 Feb 09, 2021	SELL	$75.23 - $109.23 $130,749 - $189,841	-1,738 Reduced 2.61%	64,869 $6.59 Million
Q3 2020 Nov 12, 2020	SELL	$71.31 - $109.74 $370,669 - $570,428	-5,198 Reduced 7.24%	66,607 $5.15 Million
Q2 2020 Aug 12, 2020	BUY	$62.14 - $117.21 $1.03 Million - $1.93 Million	16,497 Added 29.83%	71,805 $8 Million
Q1 2020 May 06, 2020	BUY	$60.41 - $115.92 $936,838 - $1.8 Million	15,508 Added 38.96%	55,308 $3.98 Million
Q4 2019 Feb 14, 2020	BUY	$11.44 - $123.99 $322,024 - $3.49 Million	28,149 Added 241.6%	39,800 $3 Million
Q3 2019 Nov 07, 2019	BUY	$16.05 - $27.35 $186,998 - $318,654	11,651 New	11,651 $190,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.